Volume 20, Number 1—January 2014
Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease
|Dilution||sCJD MM1 in tgHu
||vCJD in tgBov
|Positive transmission in mice||Incubation period, d||Positive transmission in mice||Incubation period, d|
|Not diluted||6/6||186 ± 10||6/6||249 ± 2|
|10−1||6/6||213 ± 15||6/6||283 ± 15|
|10−2||6/6||240 ± 13||6/6||316 ± 21|
|10−3||6/6||263 ± 24||6/6||342 ± 10|
|10-4-||6/6||296 ± 26||6/6||453 ± 66|
|10−5||6/6||323 ± 29||4/6||499 ± 17|
|Infectious titer, ID50/g of brain (95% CI)||106.67 (106.33−106.97)||106.33 (105,84 −106.82)|
*sCJD, sporadic Creutzfeld-Jakob Disease; tgHu, human PrP gene ;PrP, protease-resistant prion protein; vCJD, variant CJD; tgBov transgenic mice overexpressing bovine PrP, ID, infectious dose.
†Successive 1/10 dilutions of 10% brain homogenate (frontal cortex) from patients affected by vCJD and sCJD were injected intracerebrally to tgHu (n = 6) and tgBov (n = 6) mice, respectively. Those 2 patients were different from the 1 whose blood was tested in bioassay (Table 2). Mice were euthanized when they showed clinical signs of infection or after 650 days postinfection. Mice were considered infected when abnormal prion protein deposition was detected in the brain by western blot by using Sha31 monoclonal antibody, which recognizes amino acids 145–152 (YEDRYYRE) of the sheep prion protein. Infectious titers were estimated by the Spearman-Karber method (14).
- Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:767–78.
- Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG, Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis. 2012;18:901–7.
- Brown P, Cervenakova L, Diringer H. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med. 2001;137:5–13.
- Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994;35:513–29 .
- Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature. 1997;389:498–501.
- Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004;364:527–9.
- Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia. 2010;16:296–304.
- Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet. 2001;358:208–9.
- Andréoletti O, Litaise C, Simmons H, Corbiere F, Lugan S, Costes P, Highly efficient prion transmission by blood transfusion. PLoS Pathog. 2012;8:e1002782.
- Béringue V, Vilotte JL, Laude H. Prion agent diversity and species barrier. Vet Res. 2008;39:47.
- Castilla J, Gutiérrez Adán A, Brun A, Pintado B, Ramirez MA, Parra B, Early detection of PrPres in BSE-infected bovine PrP transgenic mice. Arch Virol. 2003;148:677–91.
- Padilla D, Beringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine F, Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog. 2011;7:e1001319.
- Markus RA, Frank J, Groshen S, Azen SP. An alternative approach to the optimal design of an LD50 bioassay. Stat Med. 1995;14:841–52 .
- Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 1999;39:1169–78.